Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan

References

• Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):1–9. doi:10.1016/j.jaad.2013.10.010.
   Web of Science ®Google Scholar
• Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192–199. doi:10.1111/j.1525-1470.2005.22303.x.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4s):S65–S76. doi:10.1016/j.jaci.2017.01.011.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z.
   PubMed Web of Science ®Google Scholar
• Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342. doi:10.3389/fimmu.2019.02342.
   PubMed Web of Science ®Google Scholar
• Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am J Clin Dermatol. 2020;21(6):783–798. doi:10.1007/s40257-020-00548-6.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–884. Mardoi:10.1016/j.jaci.2019.11.025.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-Severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–1055. doi:10.1001/jamadermatol.2021.3023.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi:10.1016/S0140-6736(21)00588-2.
   PubMed Web of Science ®Google Scholar
• Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181. doi:10.1016/S0140-6736(21)00589-4.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022;49(11):1158–1167. doi:10.1111/1346-8138.16549.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023;50(7):869–879. Juldoi:10.1111/1346-8138.16763.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis. J Dermatolog Treat. 2023;34(1):2212095.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib. J Dermatol. 2023;50(10):1301–1312. doi:10.1111/1346-8138.16879.
   PubMed Web of Science ®Google Scholar
• Hagino T, Yoshida M, Hamada R, et al. Therapeutic effectiveness of upadacitinib on individual types of rash in japanese patients with moderate-to-severe atopic dermatitis. J Dermatol. 2023;2023:16950. doi:10.1111/1346-8138.16950.
   Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. The eosinophil-to-Lymphocyte ratio acts as an indicator for improvement of clinical signs and itch by upadacitinib treatment in atopic dermatitis. J Clin Med. 2023;12(6):2201. doi:10.3390/jcm12062201.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5):523–532. doi:10.1001/jamadermatol.2022.0455.
   PubMed Web of Science ®Google Scholar
• Wan H, Jia H, Xia T, et al. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther. 2022;35(9):e15636.
   PubMed Web of Science ®Google Scholar
• Saeki H, Ohya Y, Furuta J, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022;71(4):448–458. doi:10.1016/j.alit.2022.06.009.
   PubMed Web of Science ®Google Scholar
• Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865–875. doi:10.1136/annrheumdis-2020-219012.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. doi:10.1186/s13075-019-1964-1.
   PubMed Web of Science ®Google Scholar
• Meng J, Li Y, Fischer MJM, et al. Th2 modulation of transient receptor potential channels: an unmet therapeutic intervention for atopic dermatitis. Front Immunol. 2021;12:696784. doi:10.3389/fimmu.2021.696784.
   PubMed Web of Science ®Google Scholar
• Kunimura K, Fukui Y. The molecular basis for IL-31 production and IL-31-mediated itch transmission: from biology to drug development. Int Immunol. 2021;33(12):731–736. doi:10.1093/intimm/dxab065.
   PubMed Web of Science ®Google Scholar
• Vittrup I, Krogh NS, Larsen HHP, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046–1055. doi:10.1111/jdv.18849.
   PubMed Web of Science ®Google Scholar
• Maarouf M, Saberian C, Lio PA, et al. Head-and-neck dermatitis: diagnostic difficulties and management pearls. Pediatr Dermatol. 2018;35(6):748–753. doi:10.1111/pde.13642.
   PubMed Web of Science ®Google Scholar
• Darabi K, Hostetler SG, Bechtel MA, et al. The role of malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol. 2009;60(1):125–136. Jandoi:10.1016/j.jaad.2008.07.058.
   PubMed Web of Science ®Google Scholar
• Chu H, Kim SM, Zhang K, et al. Head and neck dermatitis is exacerbated by malassezia furfur colonization, skin barrier disruption, and immune dysregulation. Front Immunol. 2023;14:1114321. doi:10.3389/fimmu.2023.1114321.
   PubMed Web of Science ®Google Scholar
• Uchida H, Kamata M, Egawa S, et al. Newly developed erythema and red papules in the face and neck with detection of demodex during dupilumab treatment for atopic dermatitis improved by discontinuation of dupilumab, switching to upadacitinib or treatment with oral ivermectin: a report of two cases. J Eur Acad Dermatol Venereol. 2023;37(3):e300–e302. doi:10.1111/jdv.18743.
   PubMed Web of Science ®Google Scholar
• Gori N, Ippoliti E, Antonelli F, et al. Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment. Clin Exp Dermatol. 2023;48(5):558–559. doi:10.1093/ced/llad040.
   PubMed Web of Science ®Google Scholar
• Fujita H, Asahina A, Sugaya M, et al. Differential production of Th1- and Th2-type chemokines by mouse langerhans cells and splenic dendritic cells. J Invest Dermatol. 2005;124(2):343–350. doi:10.1111/j.0022-202X.2004.23607.x.
   PubMed Web of Science ®Google Scholar
• Kim BS, Siracusa MC, Saenz SA, et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med. 2013;5(170):170ra16. doi:10.1126/scitranslmed.3005374.
   PubMed Web of Science ®Google Scholar
• Luo J, Zhu Z, Zhai Y, et al. The role of TSLP in atopic dermatitis: from pathogenetic molecule to therapeutical target. Mediators Inflamm. 2023;2023:7697699–7697698.
   PubMed Web of Science ®Google Scholar
• Kunsleben N, Rüdrich U, Gehring M, et al. IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31. J Invest Dermatol. 2015;135(7):1908–1911. doi:10.1038/jid.2015.106.
   PubMed Web of Science ®Google Scholar
• Nakashima C, Otsuka A, Kabashima K. Interleukin-31 and interleukin-31 receptor: new therapeutic targets for atopic dermatitis. Exp Dermatol. 2018;27(4):327–331. doi:10.1111/exd.13533.
   PubMed Web of Science ®Google Scholar
• Chalubinski M, Wojdan K, Luczak E, et al. IL-33 and IL-4 impair barrier functions of human vascular endothelium via different mechanisms. Vascul Pharmacol. 2015;73:57–63. doi:10.1016/j.vph.2015.07.012.
   PubMed Web of Science ®Google Scholar
• Leung DYM, Bissonnette R, Kreimer S, et al. Dupilumab inhibits vascular leakage of blood proteins into atopic dermatitis skin. J Allergy Clin Immunol Pract. 2023;11(5):1421–1428. doi:10.1016/j.jaip.2023.03.020.
   PubMed Web of Science ®Google Scholar
• Amarbayasgalan T, Takahashi H, Dekio I, et al. Content of vascular endothelial growth factor in stratum corneum well correlates to local severity of acute inflammation in patients with atopic dermatitis. Int Arch Allergy Immunol. 2012;157(3):251–258. doi:10.1159/000327556.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676. doi:10.1038/nm0603-669.
   PubMed Web of Science ®Google Scholar
• Ashina K, Tsubosaka Y, Kobayashi K, et al. VEGF-induced blood flow increase causes vascular hyper-permeability in vivo. Biochem Biophys Res Commun. 2015;464(2):590–595. doi:10.1016/j.bbrc.2015.07.014.
   PubMed Web of Science ®Google Scholar
• Livesey A, Garty F, Shipman AR, et al. Lactate dehydrogenase in dermatology practice. Clin Exp Dermatol. 2020;45(5):539–543. doi:10.1111/ced.14134.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wu CM, Targ S, et al. IL-21 is a broad negative regulator of IgE class switch recombination in mouse and human B cells. J Exp Med. 2020;217(5):e20190472.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions; [cited 2021 Sep 1. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death.
   Google Scholar